Agonist and antagonist-dependent internalization of the human vasopressin V2 receptor

被引:35
|
作者
Pfeiffer, R
Kirsch, J
Fahrenholz, F
机构
[1] Univ Mainz, Inst Biochem, D-55099 Mainz, Germany
[2] Max Planck Inst Hirnforsch, D-60528 Frankfurt, Germany
关键词
vasopressin; human V-2 receptor; receptor internalization; desensitization; antagonists;
D O I
10.1006/excr.1998.4159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this report we demonstrate that in HEK293 cells stably expressing the human V-2 vasopressin receptor, ligand-induced internalization of the hormone receptor occurs via the clathrin-dependent pathway. Studies of receptor trafficking either by direct visualization of the V-2 receptor by confocal microscopy or binding experiments show a rapid internalization (half-time 6-7 min), Blocking of the clathrin-dependent pathway by hypertonic sucrose increased vasopressin-induced cellular cAMP production and decreased the desensitization of the V-2 receptor-adenylyl cyclase system. Thus, internalization appears to be a major regulatory mechanism terminating vasopressin action in HEK293 cells. Two antagonists of the vasopressin V-2 receptor exerted different effects on receptor internalization, as determined by confocal fluorescence microscopy, The nonpeptidic antagonist OPC31260 did not induce any visible receptor internalization, whereas the peptidic antagonist d(CH2)(5)[D-Tyr(Et)(2),Val(4),Lys(8), Tyr-NH29]VP induced a slow but substantial receptor internalization. These results suggest that long-term treatment with peptidic V-2 receptor antagonists might lead to desensitization. (C) 1998 Academic Press.
引用
收藏
页码:327 / 339
页数:13
相关论文
共 50 条
  • [1] Tolvaptan, Vasopressin V2 Receptor Antagonist
    Inomata, Takayuki
    JOURNAL OF CARDIAC FAILURE, 2010, 16 (09) : S135 - S135
  • [2] Molecular modeling of the human vasopressin V2 receptor/agonist complex
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1998, 12 (03) : 275 - 287
  • [3] Molecular modeling of the human vasopressin V2 receptor/agonist complex
    Cezary Czaplewski
    Rajmund Kaźmierkiewicz
    Jerzy Ciarkowski
    Journal of Computer-Aided Molecular Design, 1998, 12 : 275 - 287
  • [4] ANTAGONIST-DEPENDENT AND ANTAGONIST-INDEPENDENT STEPS IN THE MECHANISM OF ADRENERGIC-RECEPTOR INTERNALIZATION
    VONZASTROW, M
    KOBILKA, BK
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (28) : 18448 - 18452
  • [5] Molecular modelling of the vasopressin V2 receptor/antagonist interactions
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    ACTA BIOCHIMICA POLONICA, 1998, 45 (01) : 19 - 26
  • [6] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [7] Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia
    Madias, Nicolaos E.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (02) : 184 - 187
  • [8] Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg, Arthur
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 50 (06) : 904 - 907
  • [9] Constitutive internalisation of the human V2 vasopressin receptor
    Hermosilla, R
    Schmidt, A
    Schwieger, I
    Oksche, A
    Schülein, R
    Wiesner, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R18 - R19
  • [10] Constitutive internalisation of the human V2 vasopressin receptor
    Hermosilla, R
    Schmidt, A
    Schwieger, I
    Oksche, A
    Schülein, R
    Wiesner, B
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R18 - R18